Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Nanoviricides Inc (NNVC)

Nanoviricides Inc (NNVC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,834
  • Shares Outstanding, K 11,610
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,110 K
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.76
Trade NNVC with:

Options Overview Details

View History
  • Implied Volatility 435.42% ( +190.14%)
  • Historical Volatility 66.21%
  • IV Percentile 90%
  • IV Rank 40.78%
  • IV High 1,033.29% on 12/13/22
  • IV Low 23.67% on 03/14/22
  • Put/Call Vol Ratio 0.17
  • Today's Volume 28
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 6,899
  • Open Int (30-Day) 6,930

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +38.10%
on 01/03/23
1.5399 -5.84%
on 01/18/23
+0.2500 (+20.83%)
since 12/23/22
3-Month
1.0500 +38.10%
on 01/03/23
1.7900 -18.99%
on 11/01/22
-0.2200 (-13.17%)
since 10/26/22
52-Week
1.0400 +39.42%
on 05/12/22
3.8800 -62.63%
on 08/04/22
-0.8200 (-36.12%)
since 01/26/22

Most Recent Stories

More News
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT

SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech...

NNVC : 1.4500 (unch)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 27.85 (-0.21%)
OCEL : 0.0178 (-1.11%)
BRTX : 3.02 (-1.17%)
MDXG : 3.81 (+7.32%)
NNVC : 1.4500 (unch)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 0.0178 (-1.11%)
BRTX : 3.02 (-1.17%)
MDXG : 3.81 (+7.32%)
NNVC : 1.4500 (unch)
VCEL : 27.85 (-0.21%)
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage

SHELTON, CT / ACCESSWIRE / October 14, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022...

NNVC : 1.4500 (unch)
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

SHELTON, CT / ACCESSWIRE / August 9, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.4500 (unch)
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

SHELTON, CT / ACCESSWIRE / August 4, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.4500 (unch)
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application

SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.4500 (unch)
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis

SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.4500 (unch)
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program

SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.4500 (unch)
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready

SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.4500 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 1.4998
2nd Resistance Point 1.4899
1st Resistance Point 1.4699
Last Price 1.4500
1st Support Level 1.4400
2nd Support Level 1.4301
3rd Support Level 1.4101

See More

52-Week High 3.8800
Fibonacci 61.8% 2.7951
Fibonacci 50% 2.4600
Fibonacci 38.2% 2.1249
Last Price 1.4500
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar